Liječenje raka pluća s pozitivnim receptorom epidermnog faktora rasta

master's thesis

• Title (english): Treatment for epidermal growth factor receptor mutation positive lung cancer
• Author: Graciela Carević
• Mentor: Jasmina Marić Brozić (mentor)
• Committee member: Nikola Đaković (predsjednik povjerenstva)
• Committee member: Marko Jakopović (član povjerenstva)
• Committee member: Jasmina Marić Brozić (član povjerenstva)
• Granter: University of Zagreb; School of Medicine; (Department of Clinical Oncology); Zagreb
• Defense date and country: 2024-07-12, Croatia
• Scientific / art field, discipline and subdiscipline: BIOMEDICINE AND HEALTHCARE; Clinical Medical Sciences; Oncology

Abstract

Rak pluća predstavlja ozbiljan globalni zdravstveni problem s obzirom da je vodeći uzrok smrti od raka diljem svijeta. Rano otkrivanje raka pluća je ključ za poboljšanje prognoze bolesnika. Nažalost, rano postavljanje dijagnoze često je izazovno, s obzirom na nespecifične simptome koje bolesnici mogu imati u početnoj fazi bolesti. Većina bolesnika stoga bude dijagnosticirana u uznapredovalom stadiju što znatno smanjuje izglede za izlječenje. No, zahvaljujući napretku u molekularnom profiliranju raka, otvara se mogućnost personaliziranog pristupa liječenju. Identificirane su ključne mutacije, poput onih na receptorima epidermalnog faktora rasta (EGFR), koje igraju važnu ulogu u razvoju raka pluća nemalih stanica (NSCLC). Otkriće inhibitora EGFR tirozin kinaze (TKI) predstavlja prekretnicu u liječenju NSCLC, budući da ova ciljana terapija poboljšava kvalitetu života bolesnika, smanjuje nuspojave i produljuje vrijeme preživljenja bez progresije bolesti. Iako su donijeli revoluciju u liječenju NSCLC, nije rijetko da bolesnici steknu rezistenciju na EGFR-TKI. Međutim, nova istraživanja i nove tehnologije otvaraju put ka razumijevanju mehanizama nastanka rezistencije i razvoju novih terapijskih strategija i daju nadu da će se u budućnosti poboljšati ishodi za sve bolesnike koji se bore s ovom teškom bolešću.

Abstract (english)

Lung cancer is a serious global health problem as it is the leading cause of cancer death worldwide. Early detection of lung cancer is key to improving patient prognosis. Unfortunately, early diagnosis is often challenging due to the non-specific symptoms that patients may experience in the early stages of the disease. Most patients are therefore diagnosed at an advanced stage, which significantly reduces the chances of a cure. However, thanks to advances in molecular profiling of cancer, the possibility of a personalized approach to treatment is opening up. Key mutations have been identified, such as those on epidermal growth factor receptors (EGFR), which play an important role in the development of non-small cell lung cancer (NSCLC). The discovery of EGFR tyrosine kinase inhibitors (TKIs) has been a breakthrough in the treatment of NSCLC, as this targeted therapy improves patients' quality of life, reduces side effects and prolongs progression-free survival. While they have revolutionized the treatment of NSCLC, it is not uncommon for patients to develop resistance to EGFR-TKIs. However, new research and new technologies are opening up the way to understanding the mechanisms of resistance and developing new therapeutic strategies, offering hope that future outcomes for all patients battling this difficult disease will be improved.

• Keywords: rak pluća nemalih stanica; inhibitori receptora epidermalnog faktora rasta; ciljana terapija
• Keywords (english): non-small cell lung cancer; epidermal growth factor receptor inhibitors; targeted therapy
• Language: croatian
• URN:NBN: urn:nbn:hr:105:089532
• Study programme: Title: Medicine; Study programme type: university; Study level: integrated undergraduate and graduate; Academic / professional title: doktor/doktorica medicine (doktor/doktorica medicine)
• Type of resource: Text
• File origin: Born digital
• Access conditions: Open access
• Created on: 2024-07-02 21:12:08